Schechter B - Search Results

1

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Friedman LM, et al. Among authors: schechter b. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1915-20. doi: 10.1073/pnas.0409610102. Epub 2005 Jan 31. Proc Natl Acad Sci U S A. 2005. PMID: 15684082 Free PMC article.

2

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.

Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Ben-Kasus T, et al. Among authors: schechter b. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3294-9. doi: 10.1073/pnas.0812059106. Epub 2009 Feb 13. Proc Natl Acad Sci U S A. 2009. PMID: 19218427 Free PMC article.

3

Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.

Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Mahlknecht G, et al. Among authors: schechter b. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8170-5. doi: 10.1073/pnas.1302594110. Epub 2013 Apr 29. Proc Natl Acad Sci U S A. 2013. PMID: 23630281 Free PMC article.

4

Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2.

Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Maron R, et al. Among authors: schechter b. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15389-94. doi: 10.1073/pnas.1313857110. Epub 2013 Sep 3. Proc Natl Acad Sci U S A. 2013. PMID: 24003140 Free PMC article.

5

Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Ben-Kasus T, Schechter B, Sela M, Yarden Y. Ben-Kasus T, et al. Among authors: schechter b. Mol Oncol. 2007 Jun;1(1):42-54. doi: 10.1016/j.molonc.2007.01.003. Epub 2007 Mar 14. Mol Oncol. 2007. PMID: 19383286 Free PMC article. Review.

6

Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding.

Mahlknecht G, Maron R, Schechter B, Yarden Y, Sela M. Mahlknecht G, et al. Among authors: schechter b. Biochem Biophys Res Commun. 2015 Sep 18;465(2):218-24. doi: 10.1016/j.bbrc.2015.07.157. Epub 2015 Aug 4. Biochem Biophys Res Commun. 2015. PMID: 26248137

7

Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.

Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M. Maron R, et al. Among authors: schechter b. Biochem Biophys Res Commun. 2019 May 21;513(1):219-225. doi: 10.1016/j.bbrc.2019.03.204. Epub 2019 Apr 3. Biochem Biophys Res Commun. 2019. PMID: 30952434

8

Therapeutic vaccines: realities of today and hopes for the future.

Sela M, Arnon R, Schechter B. Sela M, et al. Among authors: schechter b. Drug Discov Today. 2002 Jun 15;7(12):664-73. doi: 10.1016/s1359-6446(02)02296-1. Drug Discov Today. 2002. PMID: 12110243 Review.

9

Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system.

Schechter B, Arnon R, Wilchek M, Schlessinger J, Hurwitz E, Aboud-Pirak E, Sela M. Schechter B, et al. Int J Cancer. 1991 May 10;48(2):167-72. doi: 10.1002/ijc.2910480203. Int J Cancer. 1991. PMID: 1708362

10

Aromatic side-chain interactions as the origin of immunological diversity in the TyrTyrGluGlu and TyrGluTyrGlu epitopes: NMR and fluorescence evidence.

Muszkat KA, Schechter B, Sela M. Muszkat KA, et al. Among authors: schechter b. Int Immunol. 1993 Jun;5(6):591-7. doi: 10.1093/intimm/5.6.591. Int Immunol. 1993. PMID: 7688560

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters